HENDERSON, Nev., Nov. 3, 2022
/PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX)
("Volition"), a multi-national epigenetics company, announces the
launch of its Nu.Q® Vet Cancer Screening Test across the U.S. and
the forthcoming launch in Europe
by Heska Corporation (NASDAQ: HSKA) ("Heska"), a leading global
provider of advanced veterinary diagnostics, through Heska's
veterinary diagnostic laboratories.
Steve Eyl, Heska's Chief
Commercial Officer and President, scil animal company, said, "Our
team has been working closely with Volition over the past six
months and we are delighted to launch Volition's Nu.Q® Vet Cancer
Screening Test in the U.S. and announce the forthcoming launch in
Europe expected in the coming
weeks through our veterinary diagnostics laboratories. The
accurate, affordable, and non-invasive diagnostic for cancer
screening and monitoring in canines is an ideal fit within Heska's
expanding portfolio of best-in-class solutions. This is an
important achievement in our transformative work together as we
move towards the launch of our flagship point of care solution
anticipated in 2023."
Dr. Tom Butera, Chief Executive
Officer of Volition Veterinary Diagnostics Development LLC, said,
"We're thrilled to be working alongside Heska and support the
launch of the Nu.Q® Vet Cancer Screening Test in the United States and Europe. It is another key milestone for us, as
we press ahead with our aim to ensure as many veterinarians as
possible can access our Nu.Q® Vet Cancer Screening Test for
the pets and pet owners who trust them.
"There are approximately 84 million pet dogs in the United States and approximately half of
dogs will have at least one veterinary care visit each year.
Implementing the Nu.Q® Vet Cancer Screening Test at annual
wellness visits can help detect cancer at an early stage, even
before symptoms appear, allowing for a better chance of effective
treatment and improved outcomes."
Volition is developing simple, easy-to-use, cost-effective blood
tests to help diagnose and monitor a range of life-altering
diseases including cancer in both humans and animals. For more
information about Volition's Nu.Q® technology go to:
www.volition.com.
Note to editors:
- Volition Signs Exclusive $28
million License and Supply Agreement with Heska Corporation
to Distribute Nu.Q® Vet Cancer Screening Test March 29 2022
- Findings from a clinical study conducted by Volition and
Professor Wilson-Robles and the team at Texas
A&M University, peer-reviewed and published in
August 2022, showed that:
- Volition's Nu.Q® Vet Cancer Screening Test detected 76%
of systemic cancers ( including lymphoma, hemangiosarcoma, and
histiocytic sarcoma) at 97% specificity versus control.
About Heska
Heska Corporation (NASDAQ: HSKA) manufactures, develops and
sells advanced veterinary diagnostic and specialty healthcare
products through its two business segments: North America and International. Both segments
include Point of Care Lab testing instruments and consumables,
digital imaging products, software and services, data services,
allergy testing and immunotherapy, and single-use offerings such as
in-clinic diagnostic tests and heartworm preventive products. The
North America segment also
includes private label vaccine and pharmaceutical production under
third-party agreements and channels, primarily for herd animal
health. For more information, please visit www.heska.com.
About Volition
Volition is a multi-national epigenetics company that applies
its Nucleosomics™ platform through its subsidiaries to develop
simple, easy to use, cost effective blood tests to help diagnose
and monitor a range of life-altering diseases including some
cancers and diseases associated with NETosis such as sepsis and
COVID-19. Early diagnosis and monitoring have the potential not
only to prolong the life of patients but also to improve their
quality of life. The tests are based on the science of
Nucleosomics™, which is the practice of identifying and measuring
nucleosomes in the bloodstream or other bodily fluid - an
indication that disease is present.
Volition's research and development activities are centered in
Belgium, with an innovation
laboratory and office in the U.S. and additional offices in
London and Singapore.
The contents found at Volition's and Heska's website addresses
are not incorporated by reference into this document and should not
be considered part of this document. Such website addresses
are included in this document as an inactive textual references
only.
Media Enquiries:
Louise Batchelor/Debra Daglish, Volition,
mediarelations@volition.com +44 (0)7557 774620
Jon Aagaard, Heska,
investorrelations@heska.com +1 970-617-8399
Safe Harbor Statement
Statements in this press release may be "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, that concern matters that involve risks and
uncertainties that could cause actual results to differ materially
from those anticipated or projected in the forward-looking
statements. Words such as "expects," "anticipates," "intends,"
"plans," "aims," "targets," "believes," "seeks," "estimates,"
"optimizing," "potential," "goal," "suggests," "could," "would,"
"should," "may," "will" and similar expressions identify
forward-looking statements. These forward-looking statements relate
to, among other topics, Volition's estimated market
opportunity, Volition's expectations related to the potential
benefits under the License and Supply Agreement with Heska,
including the timing of product launches, the effectiveness of
Volition's blood-based diagnostic, prognostic and disease
monitoring tests, and Volition's ability to develop and
successfully commercialize such test platforms for early detection
of cancer and other diseases as well as serving as a diagnostic,
prognostic or disease monitoring tools for such diseases.
Volition's actual results may differ materially from those
indicated in these forward-looking statements due to numerous risks
and uncertainties, including, without limitation, results of
studies testing the efficacy of its tests. For instance, if
Volition fails to develop and commercialize diagnostic, prognostic
or disease monitoring products, it may be unable to execute its
plan of operations. Other risks and uncertainties include
Volition's failure to obtain necessary regulatory clearances or
approvals to distribute and market future products; a failure by
the marketplace to accept the products in Volition's development
pipeline or any other diagnostic, prognostic or disease monitoring
products Volition might develop; Volition's failure to secure
adequate intellectual property protection; Volition will face
fierce competition and Volition's intended products may become
obsolete due to the highly competitive nature of the diagnostics
and disease monitoring market and its rapid technological change;
downturns in domestic and foreign economies; and other risks
identified in Volition's most recent Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q, as well as other documents that
Volition files with the Securities and Exchange Commission. These
statements are based on current expectations, estimates and
projections about Volition's business based, in part, on
assumptions made by management. These statements are not guarantees
of future performance and involve risks, uncertainties and
assumptions that are difficult to predict. Forward-looking
statements are made as of the date of this release, and, except as
required by law, Volition does not undertake an obligation to
update its forward-looking statements to reflect future events or
circumstances.
Nucleosomics™ and Nu.Q® and their respective logos are
trademarks and/or service marks of VolitionRx Limited and its
subsidiaries. All other trademarks, service marks and trade names
referred to in this press release are the property of their
respective owners.
View original
content:https://www.prnewswire.com/news-releases/volition-announces-the-launch-of-the-nuq-vet-cancer-screening-test-in-the-us-and-europe-through-heskas-reference-laboratories-301667561.html
SOURCE VolitionRx